Usefulness of Xeloda, capecitabine for metastatic breast cancer (MBC) In the ambulatory practice

被引：0

作者：

Rodger, J

Mickiewicz, E

Giacomi, N

Vigo, S

Tatangelo, M

Formiels, H

Coppola, F

Jovtis, S

Lastiri, F

机构：

[1] Angel H Roffo, Buenos Aires, DF, Argentina

[2] Breast Clin Mama, Buenos Aires, DF, Argentina

[3] Sanat Britan Rosario, Buenos Aires, DF, Argentina

[4] Hosp Aleman, Buenos Aires, DF, Argentina

[5] Hosp Churruca, Buenos Aires, DF, Argentina

来源：

EUROPEAN JOURNAL OF CANCER | 2002年 / 38卷

关键词：

D O I：

10.1016/S0959-8049(02)80201-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

115

引用

页码：S68 / S68

页数：1

共 50 条

[1] Photoeruption in a patient treated with capecitabine (Xeloda) for metastatic breast cancer
Willey, A
Glusac, EJ
Bolognia, JL
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 47 (03) : 453 - 453
[2] A phase II study capecitabine (xeloda) in antracyclin-refractory, and antracyclin and docetaxel-refractory metastatic breast cancer (MBC)
Semiglazova, T
Gershanovich, ML
Semiglazov, VV
EUROPEAN JOURNAL OF CANCER, 2002, 38 : S97 - S97
[3] An early phase 2 study with XELODA™ (capecitabine) in patients with metastatic breast cancer
Saeki, T
Takashima, S
Terashima, M
Tabei, T
Enomoto, K
Tominaga, T
Kimura, T
Miura, S
Koyama, H
Konishi, Y
Oka, T
Naito, Y
Sonoo, H
Toge, T
Dohi, K
Nomizu, T
Taguchi, T
ANNALS OF ONCOLOGY, 1998, 9 : 155 - 155
[4] Phase III trial of capecitabine (Xeloda®) plus bevacizumab (Avastin™) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane.
Miller, KD
Rugo, HS
Cobleigh, MA
Marcom, PK
Chap, LI
Holmes, FA
Fehrenbacher, L
Overmoyer, BA
Reimann, JD
Vassel, AV
Langmuir, VK
BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S37 - S37
[5] Reduced dose of Capecitabine and Docetaxel in treatment of metastatic breast cancer (MBC)
Iravani, Masood
ANNALS OF ONCOLOGY, 2004, 15 : 46 - 46
[6] Efficacy and tolerability of capecitabine (X) monotherapy in metastatic breast cancer (MBC)
Vasev, Nikola
ANNALS OF ONCOLOGY, 2006, 17 : 75 - 75
[7] Optimizing the management of HER2-negative metastatic breast cancer with capecitabine (Xeloda)
Leonard, R
Miles, D
Reichardt, P
Twelves, C
SEMINARS IN ONCOLOGY, 2004, 31 (05) : 21 - 28
[8] Systematic review of the clinical effectiveness and costeffectiveness of capecitabine (Xeloda®) for locally advanced and/or metastatic breast cancer
Jones, L
Hawkins, N
Westwood, M
Wright, K
Richardson, G
Riemsma, R
HEALTH TECHNOLOGY ASSESSMENT, 2004, 8 (05) : 1 - +
[9] Xeloda® in the treatment of metastatic breast cancer
Blum, JL
ONCOLOGY, 1999, 57 : 16 - 20
[10] Capecitabine (X) in the first-line treatment of metastatic breast cancer (MBC).
Harbeck, N.
Kaufmann, M.
Siedentopf, F.
Dalivoust, P.
Debled, M.
Robert, N. J.
O'Shaughnessy, J.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

← 1 2 3 4 5 →